The future of a partially effective HIV vaccine: assessing limitations at the population level.

ABSTRACT:

Objectives

Mathematical models have unanimously predicted that a first-generation HIV vaccine would be useful and cost-effective to roll out, but that its overall impact would be insufficient to reverse the epidemic. Here, we explore what factors contribute most to limiting the impact of such a vaccine.

Methods

Ranging from a theoretical ideal to a more realistic regimen, mirroring the one used in the currently ongoing trial in South Africa (HVTN 702), we model a nested hierarchy of vaccine attributes such as speed of scale-up, efficacy, durability, and return rates for booster doses.

Results

The predominant reasons leading to a substantial loss of vaccine impact on the HIV epidemic are the time required to scale up mass vaccination, limited durability, and waning of

SUBMITTER: Selinger C 

PROVIDER: S-EPMC6614161 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature